naltrexone and guanfacine

naltrexone has been researched along with guanfacine in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's3 (30.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Gossop, M; Legarda, JJ1
Intengan, HD; Smyth, DD1
Pachler, M; Scahill, L1
Blokhina, E; Burakov, A; Kosten, TR; Krupitsky, E; Masalov, D; Palatkin, V; Romanova, TN; Sinha, R; Tsoy, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Yaroslavtseva, T; Zvartau, E1
Fredriksson, I; Jardemark, K; Jayaram-Lindström, N; Nylander, E; Nyström, E; Steensland, P; Wirf, M1
Blokhina, EA; Burakov, AM; Bushara, EM; Grininko, AY; Kosten, T; Krupitsky, EM; Masalov, DV; Palatkin, VY; Romanova, TN; Sinha, R; Tiurina, AA; Verbitskaya, VE; Yaroslavtseva, TS; Zvartau, EE1
McKee, SA; Ramchandani, VA; Roberts, W; Verplaetse, TL1

Reviews

3 review(s) available for naltrexone and guanfacine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Treatment of hyperactivity in children with pervasive developmental disorders.
    Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc, 2007, Volume: 20, Issue:1

    Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child Psychiatry; Dopamine Agents; Guanfacine; Humans; Methylphenidate; Naltrexone; Narcotic Antagonists; Patient Selection; Treatment Outcome

2007
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
    Alcoholism, clinical and experimental research, 2021, Volume: 45, Issue:1

    Topics: Adrenergic alpha-2 Receptor Agonists; Alcohol Deterrents; Alcohol-Related Disorders; Clinical Trials as Topic; Guanfacine; Humans; Naltrexone; Patient Selection

2021

Trials

2 trial(s) available for naltrexone and guanfacine

ArticleYear
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
    Drug and alcohol dependence, 2013, Oct-01, Volume: 132, Issue:3

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Guanfacine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Russia; Secondary Prevention; Young Adult

2013
[A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:10

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesics, Opioid; Double-Blind Method; Drug Therapy, Combination; Female; Guanfacine; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Secondary Prevention; Treatment Outcome; Young Adult

2015

Other Studies

5 other study(ies) available for naltrexone and guanfacine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation.
    Drug and alcohol dependence, 1994, Volume: 35, Issue:2

    Topics: Administration, Oral; Adult; Conscious Sedation; Drug Administration Schedule; Follow-Up Studies; Guanfacine; Heroin Dependence; Humans; Intensive Care Units; Length of Stay; Male; Midazolam; Naltrexone; Neurologic Examination; Patient Admission; Premedication; Substance Abuse Detection; Substance Withdrawal Syndrome

1994
Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:1

    Topics: Adrenergic alpha-Agonists; Animals; Body Water; Brimonidine Tartrate; Guanfacine; Idazoxan; Kidney; Male; Naltrexone; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2

1997
Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Mar-13, Volume: 40, Issue:5

    Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Disease Models, Animal; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Ethanol; Glutamic Acid; Guanfacine; Male; Naltrexone; Prefrontal Cortex; Pyramidal Cells; Rats, Wistar; Tissue Culture Techniques; Treatment Outcome

2015